Information Provided By:
Fly News Breaks for May 13, 2019
May 13, 2019 | 09:08 EDT
As previously reported, Evercore ISI analyst Vijay Kumar upgraded Boston Scientific to Outperform and raised his price target to $42.50 from $39. The analyst says that the "healthy skepticism" toward his outlook for the company's back half revenue growth potential "creates an opportunity", stating that the worst case scenario of Boston Scientific's paclitaxel coated devices being pulled from market is off the table. Instead, Kumar believes that the company can generate 7%-8% revenue growth into FY20 - the highest rate among its peers - while offering a discount valuation.
News For BSX From the Last 2 Days
Jun 19, 2019 | 07:53 EDT
The Panel will discuss and make recommendations on information related to recent observations of increased long-term mortality in peripheral arterial disease patients treated with paclitaxel-coated balloons and paclitaxel-eluting stents compared to patients treated with uncoated comparator devices in a two day meeting being held in Gaithersburg, MD on June 19-20 at 8 am. Webcast Link